Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for Urinary Incontinence in Neurogenic Detrusor Overactivity
NCT02660138Phase 3Terminated
- Sponsor
- Ipsen
- Start
- Mar 2016
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of abobotulinumtoxinA in neurogenic detrusor overactivity (NDO) (4 arms), sponsored by Ipsen. Primary endpoint: Mean Change From Baseline in Weekly Number of UI Episodes at 6 weeks. Started Mar 2016; status: terminated.
02
Drugs
abobotulinumtoxinA
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT02660138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02660138.